The funding round was led by Archangels, the Edinburgh-based, long-running business angel syndicate, with additional participation from the University of Edinburgh’s Old College Capital, St. Andrews-based Eos Advisory, and Hanna Capital SEZC.

The in-development Lifeglov is a soft robotic glove tailored towards patients who’ve lost upper limb mobility and movement, particularly patients who’ve had a stroke. The glove is being built to aid with the opening and closing strength of the hand, and to also report key metrics concerning the patient’s rehabilitative progress.

The glove’s initial application is in the upper limb rehabilitation market, but it is anticipated that the technology will have a range of clinical applications, including lower limb.

A Digital Therapy Platform is set to accompany the glove, providing patients with exercises to rebuild strength and mobility.

With the sizable sum, Bioliberty aims to complete the development of the glove’s trial product, and finalise the development of the Digital Therapy Platform. The funding is also anticipated to fund the business through obtaining FDA approval, and early commercial engagement with U.S. rehabilitation clinics.

Just last week, DIGIT reported that Rowan Armstrong, the CEO of Bioliberty, had been announced as one of the 14 Scottish entrepreneurs who will travel to New York as part of Foras’ excursion programme, providing the entrepreneurs with the opportunity to pitch their businesses to U.S. investors.

Recommended

• Scot-Secure 2023 | Delivering Impactful Cybersecurity Workshops
• Capita Outage Confirmed a Cyber-attack
• Continuous Learning Vital to Career Development

Commenting on the £2.2m, Archangels-led funding, Armstrong said: “Our aim at Bioliberty is to empower every human to live a longer independent life by providing assistive robotics and rehabilitative technologies.

“The Lifeglov is a first step on this journey and the funding announced today will allow us to complete its development, along with our software platform, while preparing the runway for our US sales push.

“We’re confident in our technology and excited by the benefits it can deliver for both patients and occupational therapists.”

Niki McKenzie, Joint Managing Director at Archangels, also said: “Bioliberty has developed a highly effective solution for helping patients with hand weakness, with the potential to improve the quality of life for millions worldwide.

“We believe its technology has far-reaching benefits beyond this first application, providing the business with an excellent opportunity to grow quickly from its base here in Scotland.

“Archangels is excited to be supporting the team as they finalise what we hope will be the first of many products and start scaling up their sales activity.”